Top Markets
Coin of the day
Lytix Biopharma AS Lytix Biopharma AS

Lytix Biopharma AS

LYTIX
株式のランク #24450
Based in Oslo, Norway, Lytix Biopharma ASA is a clinical-stage biotechnology... Based in Oslo, Norway, Lytix Biopharma ASA is a clinical-stage biotechnology firm dedicated to advancing innovative immunotherapies for cancer treatment. Its primary drug candidate, LTX-315, is an oncolytic molecule currently undergoing Phase II clinical trials. This therapy is formulated for intratumoral injection, aiming to provide localized treatment for solid tumors. Additionally, Lytix Biopharma is developing LTX-401, another oncolytic molecule in its preclinical phase, specifically designed to target deep-seated cancerous lesions, including those found in liver cancer. The company was established in 2003.
株価
$0.78611575
時価総額
$60.45M
変化(1日)
0.00%
変化(1年)
-12.06%
NO
取引 Lytix Biopharma AS (LYTIX)

カテゴリー

Lytix Biopharma AS(LYTIX)の配当利回りの履歴
Lytix Biopharma AS(銘柄コード: LYTIX)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Lytix Biopharma AS(LYTIX)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)